72 results about "Optic nerve" patented technology

The invention discloses a retina thickness prediction method and system based on a multi-modal image, and the method and system achieve the effective estimation of the retina thickness under a low-cost condition through feature alignment and fusion modeling, and improve the basic screening and follow-up visit capability. According to the invention, through fusion of the multi-mode retina image data, the structure and function information of the optic nerve can be more comprehensively obtained, and the prediction accuracy of the thickness of the retina nerve fiber layer (RNFL) is improved. The OCT high-resolution hierarchical structure and the wide-view texture features of the eye fundus image are combined, so that anatomy and pathological states of optic nerves can be truly restored. The method can be used as an auxiliary method for early screening and early warning of optic neurodegenerative diseases such as glaucoma, and provides support for low-cost and high-efficiency primary screening and clinical auxiliary decision making.

A system for hypertensive retinopathy (HTNR) detection includes a processor and a memory, including instructions stored thereon, which when executed by the processor, cause the system to: preprocess a retinal image using contrast enhancement, noise reduction and / or resolution normalization; segment a plurality of vessels from the preprocessed retinal image to generate a vessel segmentation map; detect a retinal marker, a vascular marker and / or an optic disc marker in the preprocessed retinal image using a first machine learning model; generate a severity score based on the detections; determine that the severity score exceeds a predefined threshold; and generate an output indicating a presence of HTNR based on the vessel segmentation map and the severity score using a second machine learning model.

The invention provides an implantable retina photon nerve repairing method and device, and relates to the field of implantable nerve regulation and control. The method comprises the following steps: acquiring a target image in a current visual field of a user based on external wearing equipment; adopting an edge detection algorithm to extract visual key features in the target image; based on the visual key features, time control pulse coding is adopted to generate a target stimulation pattern; performing neural feedback acquisition based on the target stimulation pattern, and acquiring neural electrical activity information through a feedback electrode preset on an implanted chip; based on the neural electrical activity information, the target stimulation pattern is dynamically adjusted through an adaptive optimization algorithm to perform optic nerve repair. The problem that a traditional implantable retina photon nerve repairing method is poor in retina photon nerve repairing effect is solved.

The invention provides an intermediate-frequency carrier and low-frequency modulated wave composite output control method, which comprises the following steps of: acquiring spatial intensity change distribution of a composite waveform in optic nerve tissue, and acquiring an actual measurement value of a carrier intensity distribution field by combining a microtube skeleton polymerization rate and an extension orientation angle of growth cone propulsion, forming basic data of an initial distribution field; extracting candidate output of an optimal waveform modulation combination from the adjusted envelope gradual change speed control combination, comparing an actual path of directional extension with an expected damage repair track through track overlapping degree measurement, and determining a quantization result of the deviation degree of the extension path; and performing deviation degree classification processing on the extension path deviation degree quantification result, obtaining a high deviation subset in a classification result, generating a compensation signal in combination with an aggregation rate change development trend, and obtaining a compensated composite waveform output combination.

The invention relates to application of graphene-(RADA-IKVAV)-pranoprofen, eye drops and a preparation method of the eye drops. The invention relates to graphene-(RADA-IKVAV)-pranoprofen, the graphene-(RADA-IKVAV)-pranoprofen comprises graphene-polyacrylic acid, self-assembled oligopeptide RADA-IKVAV and pranoprofen, the self-assembled oligopeptide RADA-IKVAV is connected with the graphene-polyacrylic acid through a chemical bond, and the pranoprofen is loaded on the surface of the graphene-polyacrylic acid. The eye drops provided by the invention comprise graphene-(RADA-IKVAV)-pranoprofen, so that the drug loading capacity of pranoprofen in the eye drops is increased, the bioavailability of drugs is improved, and the eye drops are used for inhibiting eye inflammation; the coupled oligopeptide RADA-IKVAV simulates an extracellular environment, provides a suitable microenvironment for eyes, promotes nerve repair and regeneration by influencing nerve growth factors, and promotes optic nerve repair.

The invention discloses Hangzhou white chrysanthemum-derived exosome-like nano-vesicles, a preparation method thereof and application of the nano-vesicles in treatment of optic nerve retinal degeneration diseases. In-vitro experiments show that the Hangzhou white chrysanthemum-derived exosome-like nano-vesicles provided by the invention can effectively inhibit glutamic acid-induced retinal cell oxidative stress and mitochondrial injury and improve the cell activity. In-vivo experiments show that the survival rate of ganglion cells in the retina of an NMDA injury model mouse can be remarkably improved by injecting the Hangzhou white chrysanthemum-derived exosome-like nano-vesicle into a vitreous cavity, and the visual electrophysiological function of the NMDA injury model mouse can be improved. The invention provides a new thought and method for treatment of optic nerve retinal degeneration diseases, and has a wide application prospect. In addition, the preparation method of the Hangzhou white chrysanthemum-derived exosome-like nano-vesicle provided by the invention is simple, and has the advantages of low cost, wide applicability, good safety, no animal-derived components and the like.

This invention belongs to the field of animal model technology and discloses a method and system for constructing a NMOSD mouse model. The method includes extracting NMO-IgG from patient plasma replacement fluid, actively immunizing mice with an AQP4 p201-220 peptide emulsion, and injecting NMO-IgG to establish an NMOSD animal model. This invention uses active immunization with AQP4 p201-220 peptide combined with an antigen adjuvant, and then injects patient-derived NMO-IgG on this basis. Compared with other existing animal models, the characteristic clinical manifestations of NMOSD, including the detection of peripheral blood AQP4-IgG autoantibodies and the characteristic loss of AQP4 and GFAP proteins in the retina, optic nerve, and spinal cord, are more significant, more objectively reflecting the disease characteristics of NMOSD and providing a new research platform for related studies.

Described herein is a base editing system for correcting mutations G3460A, G11778A, or T14484C in mitochondrial DNA of a patient with Leber hereditary optic neuropathy (LHON) to a normal genotype. Also, described herein is a method for correcting a mutation in the mitochondrial genes of a patient with LHON to a normal genotype using a base editor that recognizes specific sites in the mitochondrial genes of the patient with LHON and has an activity of specifically correcting the adenine base at position 3460 or 11778, or the cytosine base at position 14484, by using a fusion protein or a polynucleotide encoding such a fusion protein. The base editor or nucleotide described herein may correct DNA mutations specific to LHON in a cellular or extracellular in vitro environment. Thus, described herein is also the use of the substance in the prevention or treatment of LHON.

Pharmaceutical compositions are disclosed in the form of orosoluble suckable and chewable tablets consisting of citicoline, nicotinamide and pharmaceutically acceptable excipients, for use in the prevention and / or treatment of degeneration of the optic nerve and retinal nerve cells resulting from glaucoma.

The invention provides an implantable optic nerve brain-computer interface system, and the system comprises a first electrode matrix which is disposed in a first region to form a first spatial layout, and is used for collecting a first electric signal at a corresponding position of a preset sampling region of the first region; the second electrode matrix is arranged in the second area to form a second space layout and is used for receiving a modulation signal of the first electric signal; the conversion module is used for mapping row and column positions between the electrodes in the first electrode matrix and the electrodes in the second electrode matrix according to a spatial layout rule of the electrode matrixes; and the first electric signal is modulated, so that a modulated signal of the first electric signal is applied to the second region or a corresponding position below the second region through the second electrode matrix. The first electric signal in the specific area is collected through the first electrode matrix, and the first electric signal is redirected and modulated through the conversion module, so that the first electric signal is used as a targeted stimulation signal and is applied to the corresponding targeted area through the second electrode matrix, and effective electric stimulation is achieved.

This invention belongs to the field of biomedical technology, specifically relating to an engineered exosome and its applications. This invention is the first to discover that PCDH12 is specifically highly expressed in the trabecular meshwork tissue of glaucoma patients. Based on this target, engineered exosomes loaded with PCDH12 antibodies were successfully developed. These engineered exosomes can achieve non-invasive and precise targeted delivery to the trabecular meshwork tissue. In glaucoma model mouse experiments, they not only significantly reduced intraocular pressure but also effectively protected the optic nerve. The non-invasive and precise delivery strategy proposed in this invention combines potent intraocular pressure reduction with direct neuroprotection, providing a candidate solution with direct clinical translational potential for integrated "pressure reduction-neuroprotection" treatment of glaucoma.

To enable understanding of choroidal asymmetry. [Solution] In choroidal vascular images, the direction of blood vessel course is determined for each of several pairs of analysis points that are symmetrical with respect to the line connecting the macula and the optic nerve head. The asymmetry of each pair of analysis points is analyzed from the direction of blood vessel course of each analysis point, and the pair of analysis points with asymmetry is highlighted by enclosing them in a frame.

The application relates to the technical field of medical devices, and provides a collector for collecting trace cerebrospinal fluid of an optic nerve through a minimally invasive nasal method, which comprises a collector body, a liquid storage tube detachably mounted in the inner cavity of the collector body, a suction connector detachably connected to the distal end of the liquid storage tube, a waterproof and breathable film arranged between the liquid storage tube and the suction connector, and an electric negative pressure device detachably connected to the suction connector. The beneficial effects are as follows: an operating knife head is used to cut the optic nerve, a push button is pushed to the second position to extend the suction tube, and the cerebrospinal fluid is sucked into the liquid storage tube under the action of the electric negative pressure device; then the liquid storage tube is separated from the collector body, the waterproof and breathable film between the suction connector and the liquid storage tube is removed; then the electric negative pressure device connected to the suction connector is replaced by a liquid taking device, the liquid storage tube is cut along a shearing groove on the liquid storage tube, the liquid taking device is pushed to transfer the cerebrospinal fluid in the liquid storage tube to a liquid storage device, and the whole extraction process of the cerebrospinal fluid of the optic nerve is efficient, accurate and instantaneous.

The application relates to an artificial visual nervous system based on a bimodal neural device, comprising a bimodal visual information calculation array composed of a physical convolution kernel array and a synapse calculation array, the physical convolution kernel array is used for receiving an ambient light signal and converting into an electrical signal output, the synapse calculation array is used for receiving the electrical signal and converting into a visual signal, and the physical convolution kernel array and the synapse calculation array are both composed of a plurality of bimodal transistors. The application has excellent bimodal collaborative calculation capability, the receptive field mechanism (excitatory / inhibitory response) of a retinal bipolar cell is simulated through the physical convolution kernel array, image feature extraction and preprocessing are realized, the synaptic plasticity (LTP / LTD mechanism) of a central nervous system is simulated in combination with the synapse calculation array, high-level calculation of the visual signal is completed, and a complete visual nerve bionic system is formed by virtue of an array composed of single devices.

The present invention pertains to an optical nerve protecting agent containing an anti-low density lipoprotein receptor-related protein 1 (LRP1) antibody or fragment of the anti-LRP1 antibody.

The invention discloses eye protection liquid and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine external preparations. The eye protection liquid is prepared from a chrysanthemum extract, borneol, calculus bovis factitius, venenum bufonis, realgar, a mint extract, a pipewort extract, a feather cockscomb seed extract, a butterflybush flower extract, pearl powder and purified water according to a specific weight part ratio, and is prepared by soaking, distilling, filtering and filling. The traditional Chinese medicine composition can rapidly permeate into eyes and directly enter focus, can relieve and treat various eye diseases such as presbyopia, myopia, amblyopia, cataract and the like, has the effects of soothing liver and relieving depression, promoting blood circulation and dredging collaterals, tonifying kidney and nourishing yin, supplementing optic nerve nutrition and improving microcirculation around the eyes, has the total effective rate of 100% and the cure rate of 80-95%, and is free of side effects and drug resistance and convenient to use.

The invention discloses a fine exercise training method and system under visual guidance for improving a visual function, and relates to the technical field of visual function improvement or recovery, and the method comprises the steps: determining a minimum threshold value according to a visual test index page, and generating a training scheme of a current training period based on a visual function impaired eye visual minimum recognition threshold value; when the training scheme is executed, to-be-copied characters with the character size being the real-time training character size are called from a paper copybook or a to-be-copied electronic character library to generate a current day copybook; the trainee is in a standard sitting posture, has a preset distance from the desktop and shields the eye-care copybook to copy the current day copybook; performing visual function testing after the training scheme is executed, and adjusting the training scheme of the next training period based on the evaluation training effect. The trainee can quickly improve the vision of the patient with the impaired optic nervous system function in a short time through fine movement under visual guidance, the compliance of the patient is improved, and the system has the advantages of being low in cost, high in feasibility and capable of being extended at home.

The present invention relates to a photosensitive ring oscillator, its preparation method, and a flexible artificial retina. Specifically, the photosensitive ring oscillators (PROs) based on 2D semiconducting materials have been fabricated on flexible biological compatible substrates, which transduces light information into electrical pulse signals directly, propagating through the optic nerve. The output oscillating frequency varies quasi-linearly with the change of light intensity. The flexible electronic devices can be used as implantable biomimetic retina for artificial vision to recover the sight sense for sight-handicapped people.

The present invention relates to a base editing system having the activity of correcting (A-to-G) a G11778A mutation in the mitochondrial DNA of LHON patients. Preferably, the base editing system of the present invention uses a base editor comprising a programmable DNA binding protein, a cytosine deaminase, and an adenine deaminase, or a nucleic acid encoding these proteins, wherein the cytosine deaminase is a double-stranded DNA-specific cytosine deaminase derived from Ruminococcus.

The application discloses a teaching simulative human eyeball aqueous humor circulation model in the technical field of eyeball aqueous humor circulation models, which comprises a model box, an eyeball model assembly arranged in the model box, a functional body arranged at the top of the model box and a pump assembly arranged in the functional body. The eyeball model assembly comprises an eyeball wall, an eyeball and an optic nerve, and the eyeball wall is provided with a cornea at the front end. An iris is arranged on the side of the cornea close to the eyeball, the space between the cornea and the iris is an anterior chamber, the included angle between the cornea and the iris is an anterior chamber angle, the center of the iris is provided with a pupil, the iris is provided with a lens on the side close to the eyeball, the lens is provided with a zonular ligament around the lens, and the other end of the zonular ligament is fixedly connected with a ciliary body. The space between the iris and the lens constitutes a posterior chamber. The application has the advantages of simple structure, simulation of the process that the aqueous humor is retained in the eye to press the optic nerve when the anterior chamber angle is closed or the aqueous humor outflow passage is blocked, and convenience for medical students to understand the process that the optic nerve is pressed by the increased intraocular pressure when the aqueous humor passage is blocked.

This invention discloses an injectable hydrogel for long-term sustained release of NGF and CNTF, its preparation method, and its application in visual system diseases. The bioactive factor sustained-release hydrogel of this invention comprises a hydrogel matrix and bioactive factor microspheres loaded on the matrix; the raw materials for preparing the hydrogel matrix include chitosan, type II collagen, and hyaluronic acid; the bioactive factor microspheres comprise an inner core and a capsule wall, the inner core being a bioactive factor selected from one or both of ciliary neurotrophic factor and nerve growth factor, and the capsule wall being a polylactic acid-glycolic acid copolymer. This hydrogel can achieve long-term stable release of NTF, activating endogenous neural stem cells in the retina to generate new retinal ganglion cells. It exhibits high safety, good injectability, and a long sustained-release period, and can be used to prepare drugs for treating visual system diseases such as glaucoma, optic nerve damage, and macular degeneration.

An N-(4-trifluoromethyl)-2-cyanocrotonamide compound, a preparation method therefor, and a pharmaceutical composition and use thereof. The compound of the present invention has a more significant treatment effect on central nervous system diseases such as multiple sclerosis and neuromyelitis optica.

The invention provides a herbaceous polysaccharide exovesicle compound generated through fermentation, a preparation method thereof and application of the herbaceous polysaccharide exovesicle compound in promoting nerve repair and protecting optic nerves. The herbaceous polysaccharide exovesicle compound disclosed by the invention can maintain the thickness of the retina so as to avoid deterioration of retina injury caused by diabetes mellitus, and has an optic nerve protection function and an effect of promoting nerve repair.

The application discloses application of an S1PR1 selective agonist SAR247799 in preparation of a drug for treating neuromyelitis optica spectrum disorders. The SAR247799 can up-regulate S1PR1 expression of astrocytes, activate an S1PR1 signal path of the astrocytes, inhibit AQP4-IgG and complement-mediated damage of the astrocytes, reduce loss of AQP4, GFAP and ALDH1L1 in a lesion area of brain tissue of a neuromyelitis optica spectrum disorder model mouse, and relieve pathological damage of the neuromyelitis optica spectrum disorder model. In-vivo and in-vitro experiments prove that the SAR247799 can effectively inhibit AQP4-IgG and complement-dependent cytotoxicity effects and promote survival of the astrocytes. The application provides a novel, efficient and specific targeted drug for clinical treatment of the neuromyelitis optica spectrum disorder.

The utility model provides a kind of myopia prevention and control eye protection instrument, comprising: shell, spectrum cavity, light transmission cover, steam generator and steam outlet, the shell overhead cross section is a kind of arc structure, a group of inlaid seats for area segmentation are equipped in the middle position of shell inside, a group of light transmission covers for the light transmission of green light spectrum screen light are equipped in the inlaid seat inside, compared with prior art, the utility model has the beneficial effects as follows: by using spectrum cavity and green light spectrum screen to play the role of exciting optic nerve to myopia patient, fatigue can be quickly eliminated, and ciliary muscle relaxation can relieve spasm disease state, by using memory cotton and fitting cover to keep and provide comfortable fitting environment with patient eye, by using steam generator and annular steam pipe to provide annular steam to myopia patient eye, and promote ocular blood circulation, relieve fatigue symptoms caused by long time use of electronic equipment.

The present application relates to the field of biological medicine, in particular to nucleic acid molecule encoding human nuclear factor E2 related factor 2, expression vector and application thereof. The present application discloses a nucleotide sequence encoding human nuclear factor E2 related factor 2 (Nrf2) protein, which comprises the nucleic acid encoding human nuclear factor E2 related factor 2 (Nrf2) protein. Further disclosed is a recombinant expression vector comprising the above nucleic acid. The nucleic acid encoding human nuclear factor E2 related factor 2 (Nrf2) protein has faster expression time and higher expression level, and thus can better treat optic nerve related diseases.

A method for application of light to one or more eyes of a user is disclosed. The method comprises identification of location of an optic disk on a retina in the one or more eyes and selectively applying the light onto the optic disc to stimulate the optic disk.

FIELD: ophthalmology.SUBSTANCE: used for objective differential diagnostics of the anatomical form of the optic nerve disc (OND) deepening. Optical coherence tomography is performed on the Optovue RTVue XR Avanti System using the 3D Disc program. Images of the optic disc are obtained in the horizontal plane, a straight line is drawn between the visible boundaries of the retinal pigment epithelium (RPE) and the position and shape of the bottom of the OND deepening are assessed. When the depression is at the level of the RPE and the angle of its bottom is less than or equal to 90° a triangular shape is defined. If the depression is located above the RPE level and the angle of its bottom is more than 90° a flat shape is defined. If the depression is below the RPE level and the bottom angle is less than or equal to 90° a wedge shape is defined. If the depression is below the RPE level, and its bottom forms a base and two angles, a trapezoidal shape is defined.EFFECT: improving the accuracy, objectivity and reproducibility of determining the individual anatomical shape of the OND excavation by using a stable anatomical landmark – the RPE and standardized geometric parameters, which eliminates subjective error in diagnosis.1 cl, 7 dwg, 1 tbl, 3 ex

The present invention relates to an AI-based image processing device for segmenting an optic nerve structure to diagnose a visual abnormality. The AI-based image processing device for segmenting an optic nerve structure to diagnose a visual abnormality according to an aspect of the present invention comprises: a first encoder including a convolution block and multiple layer blocks and for calculating multi-level features from an RGB image obtained by photographing eyes; a second encoder for performing a multi-head self-attention operation on a top-level feature output from the first encoder, and applying same to a multi-layer perceptron to calculate a feature obtained by capturing spatial dimension dependency; and a decoder for: obtaining an image in which spatial features are emphasized, by repeating a process of connecting, to a result obtained by performing an attention operation on each feature remaining after excluding the top-level feature from among the multi-level features output from the first encoder and up-sampling the feature output from the second encoder, a result obtained by performing an attention operation on each feature from the upper level, performing a convolution operation, up-sampling same, and then connecting a result obtained by performing an attention operation on the next lower-level feature; and segmenting regions corresponding to an optic nerve disk and an optic nerve cup, respectively.

Apparatus for the non-invasive in-vivo determination of changes in tissue, e.g. the myelination, of the optic nerve (ON) in a biological subject, said apparatus comprising: a laser source for generating an excitation laser beam; an optical system including a fundus camera operatively associated with the laser source for use in obtaining a fundus image for illuminating the optic nerve (ON) of a subject with the excitation laser beam; a detector (13) operatively associated with the optical system and configured to detect a Raman spectrum from the optic nerve (ON) and / or surrounding cerebral spinal fluid; and a processor provided with a computer program for comparing the detected Raman spectrum to at least one reference spectrum. The reference spectrum may correspond to the myelination of the optic nerve in a normal, healthy subject, for determining the changes in the myelination of the optic nerve of the subject based on the detecting and comparing steps from the Raman spectrum.